IceCure Medical (NASDAQ:ICCM) Trading Up 0.8% – Here’s What Happened

IceCure Medical Ltd. (NASDAQ:ICCM)’s stock price traded up 0.8% on Wednesday . The company traded as high as $0.98 and last traded at $0.95. 125,625 shares were traded during mid-day trading, a decline of 73% from the average session volume of 469,709 shares. The stock had previously closed at $0.94.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a research report on Thursday, May 29th.

IceCure Medical Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.48 and a current ratio of 1.89. The company has a market cap of $52.73 million, a PE ratio of -3.39 and a beta of 0.33. The company’s 50 day moving average price is $1.07 and its 200-day moving average price is $1.17.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, May 28th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.75 million. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. During the same period in the prior year, the company earned ($0.08) earnings per share. Equities research analysts anticipate that IceCure Medical Ltd. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd raised its holdings in shares of IceCure Medical Ltd. (NASDAQ:ICCM) by 123.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,866 shares of the company’s stock after purchasing an additional 32,555 shares during the quarter. XTX Topco Ltd owned approximately 0.11% of IceCure Medical worth $65,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.